250 related articles for article (PubMed ID: 18259011)
1. Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Gerdts E; Okin PM; de Simone G; Cramariuc D; Wachtell K; Boman K; Devereux RB
Hypertension; 2008 Apr; 51(4):1109-14. PubMed ID: 18259011
[TBL] [Abstract][Full Text] [Related]
2. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Os I; Franco V; Kjeldsen SE; Manhem K; Devereux RB; Gerdts E; Hille DA; Lyle PA; Okin PM; Dahlöf B; Oparil S
Hypertension; 2008 Apr; 51(4):1103-8. PubMed ID: 18259029
[TBL] [Abstract][Full Text] [Related]
3. Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study).
Gerdts E; Franklin S; Rieck A; Papademetriou V; Wachtell K; Nieminen M; Dahlöf B; Devereux RB
Blood Press; 2009; 18(4):180-6. PubMed ID: 19562573
[TBL] [Abstract][Full Text] [Related]
4. Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study.
Gerdts E; Okin PM; Omvik P; Wachtell K; Dahlöf B; Hildebrandt P; Nieminen MS; Devereux RB
Nutr Metab Cardiovasc Dis; 2009 Jun; 19(5):306-12. PubMed ID: 19303268
[TBL] [Abstract][Full Text] [Related]
5. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
[TBL] [Abstract][Full Text] [Related]
6. Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study).
Gerdts E; Roman MJ; Palmieri V; Wachtell K; Smith G; Nieminen MS; Dahlöf B; Devereux RB
J Hum Hypertens; 2004 Jun; 18(6):417-22. PubMed ID: 15103312
[TBL] [Abstract][Full Text] [Related]
7. Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study).
Mancusi C; Gerdts E; De Simone G; Abdelhai YM; Lønnebakken MT; Boman K; Wachtell K; Dahlöf B; Devereux RB
Blood Press; 2014 Aug; 23(4):206-12. PubMed ID: 24564262
[TBL] [Abstract][Full Text] [Related]
8. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
[TBL] [Abstract][Full Text] [Related]
9. In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.
Wachtell K; Gerdts E; Palmieri V; Olsen MH; Nieminen MS; Papademetriou V; Boman K; Dahlöf B; Aurigemma GP; Rokkedal JE; Devereux RB
J Hypertens; 2010 Jul; 28(7):1541-6. PubMed ID: 20410835
[TBL] [Abstract][Full Text] [Related]
10. Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
Narayan P; Papademetriou V; Wachtell K; Gerdts E; Boman K; Nieminen MS; de Simone G; Dahlöf B; Fyhrquist F; Hoieggen A; Devereux RB
Hypertension; 2006 May; 47(5):868-73. PubMed ID: 16567586
[TBL] [Abstract][Full Text] [Related]
11. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
Gerdts E; Zabalgoitia M; Björnstad H; Svendsen TL; Devereux RB
Am J Cardiol; 2001 Apr; 87(8):980-3; A4. PubMed ID: 11305990
[TBL] [Abstract][Full Text] [Related]
12. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
Devereux RB; Dahlöf B; Gerdts E; Boman K; Nieminen MS; Papademetriou V; Rokkedal J; Harris KE; Edelman JM; Wachtell K
Circulation; 2004 Sep; 110(11):1456-62. PubMed ID: 15326072
[TBL] [Abstract][Full Text] [Related]
13. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
[TBL] [Abstract][Full Text] [Related]
14. Sex-related difference in regression of left ventricular hypertrophy with antihypertensive treatment: the LIFE study.
Bella JN; Palmieri V; Wachtell K; Liu JE; Gerdts E; Nieminen MS; Koren MJ; Zabalgoitia M; Wright JT; Dahlöf B; Devereux RB
J Hum Hypertens; 2004 Jun; 18(6):411-6. PubMed ID: 15042116
[TBL] [Abstract][Full Text] [Related]
15. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint.
Wachtell K; Rokkedal J; Bella JN; Aalto T; Dahlöf B; Smith G; Roman MJ; Ibsen H; Aurigemma GP; Devereux RB
Am J Cardiol; 2001 Jan; 87(1):54-60. PubMed ID: 11137834
[TBL] [Abstract][Full Text] [Related]
16. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
17. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
18. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
Devereux RB; Roman MJ; Palmieri V; Okin PM; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Wachtell K; Dahlöf B
J Hypertens; 2000 Aug; 18(8):1129-38. PubMed ID: 10954006
[TBL] [Abstract][Full Text] [Related]
19. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study.
Wachtell K; Palmieri V; Olsen MH; Gerdts E; Papademetriou V; Nieminen MS; Smith G; Dahlöf B; Aurigemma GP; Devereux RB
Circulation; 2002 Jul; 106(2):227-32. PubMed ID: 12105163
[TBL] [Abstract][Full Text] [Related]
20. Association of left bundle branch block with left ventricular structure and function in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Li ZB; Wachtell K; Okin PM; Gerdts E; Liu JE; Nieminen MS; Jern S; Dahlöf B; Devereux RB
J Hum Hypertens; 2004 Jun; 18(6):397-402. PubMed ID: 15071485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
